

Phenyl substituted prostaglandin analogs for glaucoma

Drugs of the Future

17, 691

DOI: [10.1358/dof.1992.017.08.187766](https://doi.org/10.1358/dof.1992.017.08.187766)

Citation Report

#	ARTICLE	IF	CITATIONS
1	Intraocular Pressure-reducing Effect of PhXA41 in Ocular Hypertension. <i>Ophthalmology</i> , 1993, 100, 1305-1311.	5.2	116
2	Intraocular Pressure-reducing Effect of PhXA41 in Patients with Increased Eye Pressure. <i>Ophthalmology</i> , 1993, 100, 1312-1317.	5.2	101
3	Interaction of PhXA41, a New Prostaglandin Analogue, With Pilocarpine. <i>JAMA Ophthalmology</i> , 1993, 111, 662.	2.4	84
4	Maintained Intraocular Pressure Reduction With Once-a-Day Application of a New Prostaglandin F ₂ ± Analogue (PhXA41). <i>JAMA Ophthalmology</i> , 1993, 111, 657.	2.4	58
5	The Effects on Aqueous Dynamics of PhXA41, a New Prostaglandin F ₂ ± Analogue, After Topical Application in Normal and Ocular Hypertensive Human Eyes. <i>JAMA Ophthalmology</i> , 1993, 111, 1351.	2.4	244
6	Cloning of the rat and human prostaglandin F ₂ ±receptors and the expression of the rat prostaglandin F ₂ ±receptor. <i>FEBS Letters</i> , 1994, 355, 317-325.	2.8	64
7	Corneal permeability to and ocular metabolism of phenyl substituted prostaglandin esters in vitro. <i>Prostaglandins Leukotrienes and Essential Fatty Acids</i> , 1994, 50, 161-168.	2.2	38
8	Ligand-controlled palladium-catalyzed intramolecular reactions of phenyl-substituted prostaglandin F ₂ ± analogues. <i>Tetrahedron</i> , 1995, 51, 9139-9154.	1.9	10
9	Effects of PhXA41, a prostaglandin analogue, and PGF ₂ ± on the corneal and intraretinal d.c. electroretinogram (ERG) of the albino rabbit eye. <i>Current Eye Research</i> , 1995, 14, 1073-1080.	1.5	5
10	Effects on Intraocular Pressure and Side Effects of 0.005% Latanoprost Applied Once Daily, Evening or Morning. <i>Ophthalmology</i> , 1995, 102, 1743-1752.	5.2	494
11	Comparison of Latanoprost and Timolol in Patients with Ocular Hypertension and Glaucoma. <i>Ophthalmology</i> , 1996, 103, 138-147.	5.2	488
12	A Six-month, Randomized, Double-masked Study Comparing Latanoprost with Timolol in Open-angle Glaucoma and Ocular Hypertension. <i>Ophthalmology</i> , 1996, 103, 126-137.	5.2	438
13	Regio- and Stereoselective Reactions of 17-Phenyl-18,19,20-trinorprostaglandin F ₂ ± Isopropyl Ester. <i>Journal of Organic Chemistry</i> , 1996, 61, 4028-4034.	3.2	14
14	POSTER COMMUNICATIONS. <i>British Journal of Pharmacology</i> , 1996, 118, 52P.	5.4	0
15	Development of a radioimmunoassay for latanoprost and its application in a long-term study in monkeys. <i>Prostaglandins Leukotrienes and Essential Fatty Acids</i> , 1996, 55, 427-432.	2.2	8
16	Latanoprost. <i>Drugs and Aging</i> , 1996, 9, 363-378.	2.7	84
17	A Comparison of Latanoprost and Timolol in Primary Open-angle Glaucoma and Ocular Hypertension. <i>JAMA Ophthalmology</i> , 1996, 114, 929.	2.4	162
18	Will Latanoprost Be the 'Wonder' Drug of the '90s for the Treatment of Glaucoma?. <i>JAMA Ophthalmology</i> , 1996, 114, 998.	2.4	16

#	ARTICLE	IF	CITATIONS
19	Latanoprost: A Review. <i>Seminars in Ophthalmology</i> , 1997, 12, 134-142.	1.6	0
20	Chapter 31. To Market, To Market - 1996. <i>Annual Reports in Medicinal Chemistry</i> , 1997, 32, 305-326.	0.9	15
21	Mediation of prostaglandin f2a-induced ocular surface hyperemia by sensory nerves in rabbits. <i>Current Eye Research</i> , 1997, 16, 886-890.	1.5	18
22	New Approaches to Antiglaucoma Therapy. <i>Journal of Medicinal Chemistry</i> , 1997, 40, 2793-2809.	6.4	87
23	Additive Ocular Hypotensive Effect of Latanoprost and Acetazolamide. <i>Ophthalmology</i> , 1997, 104, 1503-1507.	5.2	30
24	A Comparative Study of Two Dose Regimens of Latanoprost in Patients with Elevated Intraocular Pressure. <i>Ophthalmology</i> , 1997, 104, 1720-1724.	5.2	11
25	Mechanism of prostaglandin E2-, F2Î±- and latanoprost acid-induced relaxation of submental veins. <i>European Journal of Pharmacology</i> , 1997, 340, 195-201.	3.5	25
26	Î³13-Reductase dependent metabolism of prostaglandins in the mammalian brain and eye. <i>Prostaglandins Leukotrienes and Essential Fatty Acids</i> , 1997, 57, 305-310.	2.2	13
27	Structure-activity relationships and receptor profiles of some ocular hypotensive prostanoids. <i>Survey of Ophthalmology</i> , 1997, 41, S47-S52.	4.0	53
28	Initial clinical studies with prostaglandins and their analogues. <i>Survey of Ophthalmology</i> , 1997, 41, S61-S68.	4.0	49
29	Clinical dose-regimen studies with latanoprost, a new ocular hypotensive PGF2Î± analogue. <i>Survey of Ophthalmology</i> , 1997, 41, S77-S81.	4.0	23
30	Fluorescein angiographic evaluation of the effect of latanoprost treatment on blood-retinal barrier integrity: A review of studies conducted on pseudophakic glaucoma patients and on phakic and aphakic monkeys. <i>Survey of Ophthalmology</i> , 1997, 41, S83-S88.	4.0	37
31	The lack of respiratory effects of the ocular hypotensive drug latanoprost in patients with moderate-steroid treated asthma. <i>Survey of Ophthalmology</i> , 1997, 41, S111-S115.	4.0	26
32	The effect of latanoprost 0.005% once daily versus 0.0015% twice daily on intraocular pressure and aqueous humour protein concentration in glaucoma patients. A randomized, double-masked comparison with timolol 0.5%. <i>Graefe's Archive for Clinical and Experimental Ophthalmology</i> , 1997, 235, 20-26.	1.9	32
33	Prostaglandin derivatives as ocular hypotensive agents. <i>Progress in Retinal and Eye Research</i> , 1998, 17, 291-312.	15.5	75
34	Role of protein kinase C Î± in endothelin-1 stimulation of cytosolic phospholipase A2 and arachidonic acid release in cultured cat iris sphincter smooth muscle cells. <i>Lipids and Lipid Metabolism</i> , 1998, 1392, 127-144.	2.6	48
35	Effects of Prostaglandin E₂, F_{2Î±}, and Latanoprost Acid on Isolated Ocular Blood Vessels <i>In Vitro</i>. <i>Journal of Ocular Pharmacology and Therapeutics</i> , 1998, 14, 119-128.	1.4	30
36	Anterior uveitis associated with latanoprost. <i>American Journal of Ophthalmology</i> , 1998, 126, 37-41.	3.3	161

#	ARTICLE	IF	CITATIONS
37	Latanoprost treatment for glaucoma: effects of treating for 1 year and of switching from timolol. American Journal of Ophthalmology, 1998, 126, 390-399.	3.3	65
38	Î ² -Blockerâ€“Induced Complications and the Patient With Glaucoma. Archives of Internal Medicine, 1998, 158, 221.	3.8	65
39	Latanoprost twice daily is less effective than once daily: indication of receptor subsensitivity?. Current Eye Research, 1998, 17, 567-572.	1.5	38
40	Latanoprost Accelerates Disruption of the Blood-Aqueous Barrier and the Incidence of Angiographic Cystoid Macular Edema in Early Postoperative Pseudophakias. JAMA Ophthalmology, 1999, 117, 34.	2.4	159
41	Daily Cost of Newer Glaucoma Agents. Journal of Ocular Pharmacology and Therapeutics, 1999, 15, 379-388.	1.4	12
42	Latanoprost 0.005% and anterior segment uveitis. Acta Ophthalmologica, 1999, 77, 668-672.	0.3	74
43	Prostaglandin Analogues in the Treatment of Glaucoma. Drugs and Aging, 1999, 14, 387-398.	2.7	65
44	A Preliminary Risk-Benefit Assessment of Latanoprost and Unoprostone in Open-Angle Glaucoma and Ocular Hypertension. Drug Safety, 1999, 20, 505-514.	3.2	32
45	Effect of Latanoprost on Regional Blood Flow and Capillary Permeability in the Monkey Eye. JAMA Ophthalmology, 1999, 117, 1363.	2.4	33
47	Microvascular effects of selective prostaglandin analogues in the eye with special reference to latanoprost and glaucoma treatment. Progress in Retinal and Eye Research, 2000, 19, 459-496.	15.5	58
48	The additive intraocular pressure-lowering effect of latanoprost 0.005% daily once and pilocarpine 2% t.i.d. in patients with open-angle glaucoma or ocular hypertension. Graefe's Archive for Clinical and Experimental Ophthalmology, 2000, 238, 433-439.	1.9	21
49	A Pooled-Data Analysis of Three Randomized, Double-Masked, Six-Month Clinical Studies Comparing the Intraocular Pressure Reducing Effect of Latanoprost and Timolol. European Journal of Ophthalmology, 2000, 10, 95-104.	1.3	93
50	Comparison of the Efficacy and Safety of Latanoprost 0.005% Compared to Brimonidine 0.2% or Dorzolamide 2% When Added to a Topical Î ² -Adrenergic Blocker in Patients with Primary Open-Angle Glaucoma or Ocular Hypertension. Journal of Ocular Pharmacology and Therapeutics, 2000, 16, 251-259.	1.4	25
51	Therapeutic Success of Latanoprost 0.005% Compared to Brimonidine 0.2% in Patients with Open-Angle Glaucoma or Ocular Hypertension. Journal of Ocular Pharmacology and Therapeutics, 2000, 16, 557-564.	1.4	19
52	Localization of Prostaglandin E Receptor Subtypes in the Ciliary Body of Mouse Eye. Experimental Eye Research, 2000, 70, 623-628.	2.6	14
53	Design and Synthesis of 13,14-Dihydro Prostaglandin F ₂ Analogues as Potent and Selective Ligands for the Human FP Receptor. Journal of Medicinal Chemistry, 2000, 43, 945-952.	6.4	17
54	Synthesis and Biological Activity of a Novel 11a-Homo (Cyclohexyl) Prostaglandin. Journal of Medicinal Chemistry, 2000, 43, 3400-3407.	6.4	16
55	The efficacy and safety of latanoprost 0.005% once daily versus brimonidine 0.2% twice daily in open-angle glaucoma or ocular hypertension. American Journal of Ophthalmology, 2001, 131, 631-635.	3.3	67

#	ARTICLE	IF	CITATIONS
56	Synthesis and Biological Evaluation of Prostaglandin-F Alkylphosphinic Acid Derivatives as Bone Anabolic Agents for the Treatment of Osteoporosis. <i>Journal of Medicinal Chemistry</i> , 2001, 44, 4157-4169.	6.4	18
57	A Comparison of Intraocular Pressure-Lowering Effect of Prostaglandin F ₂ -?? Analogues, Latanoprost, and Unoprostone Isopropyl. <i>Journal of Glaucoma</i> , 2001, 10, 487-492.	1.6	19
58	Prostanoid Receptor Assays. <i>Current Protocols in Pharmacology</i> , 2001, 14, Unit4.18.	4.0	2
59	Latanoprost versus combined therapy with timolol plus dorzolamide: IOP-lowering effect in open-angle glaucoma. <i>Acta Ophthalmologica</i> , 2001, 79, 6-9.	0.3	21
60	Therapeutic potential of prostaglandin analogues in glaucoma. <i>Expert Opinion on Investigational Drugs</i> , 2001, 10, 679-694.	4.1	32
61	Ocular and Systemic Pharmacokinetics Of Latanoprost in Humans. <i>Survey of Ophthalmology</i> , 2002, 47, S6-S12.	4.0	130
62	Identification and Characterization of the Ocular Hypotensive Efficacy of Travoprost, a Potent and Selective FP Prostaglandin Receptor Agonist, and AL-6598, a DP Prostaglandin Receptor Agonist. <i>Survey of Ophthalmology</i> , 2002, 47, S13-S33.	4.0	73
63	Prostaglandins and Cystoid Macular Edema. <i>Survey of Ophthalmology</i> , 2002, 47, S203-S218.	4.0	288
64	The Effect of Latanoprost on Intraocular Pressure During 2 Years of Treatment. <i>Survey of Ophthalmology</i> , 2002, 47, S65-S76.	4.0	40
65	The Effect of Latanoprost Compared with Timolol in African-American, Asian, Caucasian, and Mexican Open-Angle Glaucoma or Ocular Hypertensive Patients. <i>Survey of Ophthalmology</i> , 2002, 47, S77-S89.	4.0	46
66	The Hydrolysis of Bimatoprost in Corneal Tissue Generates a Potent Prostanoid FP Receptor Agonist. <i>Survey of Ophthalmology</i> , 2002, 47, S34-S40.	4.0	80
67	Bimatoprost and Travoprost. <i>Survey of Ophthalmology</i> , 2002, 47, S105-S115.	4.0	110
68	Bimatoprost vs. Timolol. <i>Ophthalmology</i> , 2002, 109, 627-628.	5.2	4
69	Effect of 0.005% latanoprost once daily on intraocular pressure in glaucomatous patients not adequately controlled by beta-blockers twice daily: a 3-year follow-up. <i>Graefe's Archive for Clinical and Experimental Ophthalmology</i> , 2002, 240, 379-386.	1.9	34
70	The role of COX-2 in angiogenesis and rheumatoid arthritis. <i>Experimental and Molecular Pathology</i> , 2003, 74, 282-290.	2.1	66
71	A short-term study of the additive effect of latanoprost 0.005% and brimonidine 0.2%. <i>Japanese Journal of Ophthalmology</i> , 2003, 47, 473-478.	1.9	6
72	Efficacy and safety of timolol maleate/latanoprost fixed combination versus timolol maleate and brimonidine given twice daily. <i>Acta Ophthalmologica</i> , 2003, 81, 242-246.	0.3	43
73	Conjunctival hyperemia in healthy subjects after short-term dosing with latanoprost, bimatoprost, and travoprost. <i>American Journal of Ophthalmology</i> , 2003, 135, 314-320.	3.3	100

#	ARTICLE	IF	CITATIONS
74	Twenty-four-hour diurnal curve comparison of commercially available latanoprost 0.005% versus the timolol and dorzolamide fixed combination. <i>Ophthalmology</i> , 2003, 110, 1357-1360.	5.2	61
75	Morphological Changes in the Anterior Eye Segment after Long-Term Treatment with Different Receptor Selective Prostaglandin Agonists and a Prostanamide. , 2003, 44, 4419.		116
76	Studies on ocular inflammation and development of a prostaglandin analogue for glaucoma treatment. <i>Experimental Eye Research</i> , 2004, 78, 759-766.	2.6	22
77	Detection of the free acid of bimatoprost in aqueous humor samples from human eyes treated with bimatoprost before cataract surgery. <i>Ophthalmology</i> , 2004, 111, 2193-2198.	5.2	52
78	Efficacy of Bunazosin Hydrochloride 0.01% as Adjunctive Therapy of Latanoprost or Timolol. <i>Journal of Glaucoma</i> , 2004, 13, 73-80.	1.6	11
79	The Role of Prostaglandin Analogues in the Treatment of Glaucoma in the 21st Century. <i>International Ophthalmology Clinics</i> , 2004, 44, 15-27.	0.7	11
80	Latanoprost induces matrix metalloproteinase-1 expression in human nonpigmented ciliary epithelial cells through a cyclooxygenase-2-dependent mechanism. <i>FASEB Journal</i> , 2005, 19, 1929-1931.	0.5	54
81	Prostanoids in the Therapy of Glaucoma. <i>Cardiovascular Drug Reviews</i> , 2006, 24, 1-10.	4.1	40
82	Latanoprost Nonresponders with Open-Angle Glaucoma in the Japanese Population. <i>Japanese Journal of Ophthalmology</i> , 2006, 50, 153-157.	1.9	38
83	Bimatoprost for glaucoma therapy: pharmacology, clinical efficacy and controversy. <i>Expert Review of Ophthalmology</i> , 2006, 1, 141-158.	0.6	1
84	Travoprost in the treatment of glaucoma. <i>Expert Review of Ophthalmology</i> , 2007, 2, 177-183.	0.6	3
85	Bimatoprost, a novel efficacious ocular hypotensive drug now recognized as a member of a new class of agents called prostanamides. <i>Drug Development Research</i> , 2007, 68, 147-155.	2.9	12
86	Case Study: Latanoprost: Isopropylester of a Prostaglandin F ₂ Analog. , 2007, , 1281-1288.		1
88	Commercially Available Prostaglandin Analogs for the Reduction of Intraocular Pressure: Similarities and Differences. <i>Survey of Ophthalmology</i> , 2008, 53, S69-S84.	4.0	71
89	Synthesis and Pharmacological Properties of Fluorinated Prostanoids. , 2008, , 623-659.		1
90	Validated liquid chromatographic method for analysis of the isomers of latanoprost. <i>Acta Chromatographica</i> , 2008, 20, 157-164.	1.3	6
91	Microcirculation of the Ocular Fundus. , 2008, , 735-765.		5
92	The Mechanisms by Which Latanoprost Free Acid Inhibits Human Carbonic Anhydrase I and II. <i>Biological and Pharmaceutical Bulletin</i> , 2008, 31, 796-801.	1.4	5

#	ARTICLE	IF	CITATIONS
93	Fixed combination of topical brimonidine 0.2% and timolol 0.5% for glaucoma and uncontrolled intraocular pressure. <i>Clinical Ophthalmology</i> , 2008, 2, 545.	1.8	14
94	Comparison of Daytime Efficacy and Safety of Dorzolamide/Timolol Maleate Fixed Combination versus Latanoprost. <i>European Journal of Ophthalmology</i> , 2008, 18, 556-562.	1.3	2
95	A 6-month, randomized, double-masked comparison of latanoprost with timolol in patients with open angle glaucoma or ocular hypertension. <i>Acta Ophthalmologica</i> , 1996, 74, 140-144.	0.3	24
96	Sympathetic use of latanoprost 0.005% in 30 eyes. <i>Acta Ophthalmologica</i> , 1998, 76, 38-39.	0.3	1
97	First total syntheses and absolute configuration of rugulactone and 6(R)-(4-oxopent-2-enyl)-5,6-dihydro-2H-pyran-2-one. <i>Tetrahedron Letters</i> , 2009, 50, 5941-5944.	1.4	33
100	Effects of prostaglandin F ₂ analogues on endothelin-1-induced impairment of rabbit ocular blood flow: Comparison among tafluprost, travoprost, and latanoprost. <i>Experimental Eye Research</i> , 2010, 91, 853-859.	2.6	44
101	Effect of topical 0.03% flurbiprofen and 0.005% latanoprost, alone and in combination, on normal canine eyes. <i>Veterinary Ophthalmology</i> , 2011, 14, 71-79.	1.0	20
102	Development and validation of a liquid chromatography/electrospray ionization tandem mass spectrometry method for the quantification of latanoprost free acid in rabbit aqueous humor and ciliary body. <i>Journal of Mass Spectrometry</i> , 2011, 46, 1168-1174.	1.6	6
103	The Manufacture of a Homochiral 4-Silyloxycyclopentenone Intermediate for the Synthesis of Prostaglandin Analogues. <i>Organic Process Research and Development</i> , 2012, 16, 1905-1916.	2.7	26
104	^#. ^t36: TLC of Drugs Used in Obesity and Sexual Dysfunction Treatment. , 2013, , 720-723.		0
105	Simple, fast, and sensitive isocratic high-performance liquid chromatography method for the quantification of latanoprost. <i>Acta Chromatographica</i> , 2014, 26, 191-202.	1.3	1
106	Comparison of Ocular Pulse Amplitude-Lowering Effects of Tafluprost and Latanoprost by Dynamic Contour Tonometry. <i>Journal of Ocular Pharmacology and Therapeutics</i> , 2015, 31, 617-622.	1.4	4
107	Prostaglandin E ₂ -Glyceryl Ester: In Vivo Evidence for a Distinct Pharmacological Identity from Intraocular Pressure Studies. <i>Journal of Pharmacology and Experimental Therapeutics</i> , 2016, 358, 173-180.	2.5	4
108	Prostanoid Receptor Antagonist Effects on Intraocular Pressure, Supported by Ocular Biodisposition Experiments. <i>Journal of Ocular Pharmacology and Therapeutics</i> , 2016, 32, 606-622.	1.4	10
109	Effect of Switching From Latanoprost to Bimatoprost in Primary Open-Angle Glaucoma Patients Who Experienced Intraocular Pressure Elevation During Treatment. <i>Journal of Glaucoma</i> , 2016, 25, e359-e366.	1.6	5
110	Asymmetric Hydrogenation of Tetrasubstituted Cyclic Enones to Chiral Cycloalkanols with Three Contiguous Stereocenters. <i>Organic Letters</i> , 2017, 19, 3231-3234.	4.6	45
111	Discovery, characterization and clinical utility of prostaglandin agonists for the treatment of glaucoma. <i>British Journal of Pharmacology</i> , 2019, 176, 1051-1058.	5.4	46
112	Promise of latanoprost and timolol loaded combinatorial nanosheet for therapeutic applications in glaucoma. <i>Journal of King Saud University - Science</i> , 2020, 32, 1042-1047.	3.5	8

#	ARTICLE	IF	CITATIONS
113	Cloning and expression of a cDNA for the human prostanoid FP receptor.. Journal of Biological Chemistry, 1994, 269, 2632-2636.	3.4	252
114	Perspectives in the medical treatment of glaucoma. Current Opinion in Ophthalmology, 1999, 10, 99-108.	2.9	9
115	Prostaglandin analogues: past, present, and future. Ophthalmology Journal, 2017, 10, 40-52.	0.2	13
116	Prostanoid receptors (version 2019.5) in the IUPHAR/BPS Guide to Pharmacology Database. IUPHAR/BPS Guide To Pharmacology CITE, 2019, 2019, .	0.2	2
118	Prostaglandins in the Treatment of Increased Intraocular Pressure. , 1996, , 131-138.		0
119	Rapid Metabolic Responses to Prostaglandins in Cultured Cells Expressing the FP-Receptor. Advances in Experimental Medicine and Biology, 1997, 407, 231-236.	1.6	0
120	Practical pharmacogenetics for personalized management of glaucoma patients. Farmakogenetika I Farmakogenomika, 2020, , 26-34.	0.0	4
121	Ocular drug discovery and development. , 2022, , 67-89.		0